Ecosystem Over Geography Life Sciences APAC hubs
Decision brief
Answer first · skim in under a minute
Life sciences companies in Asia-Pacific are shifting from traditional geographic clustering to ecosystem-based location strategies. This article analyzes the key factors driving this change and its implications for strategic planning.
Ecosystem Over Geography Life Sciences location strategy in APAC is no longer a tax-holiday spreadsheet: WHO-Listed Authority status, EMA OPEN partners, and trial-ready networks now decide where R&D and manufacturing capital stick.
Contents10 sections
Key Takeaways
- Singapore’s HSA and Korea’s MFDS were listed as WHO-Listed Authorities on 31 October 2023—the first cohort under WHO’s transparent WLA framework.
- On 20 May 2024 WHO expanded HSA’s WLA scope and approved the US FDA and the European medicines regulatory network as WLAs, raising the bar for reliance-based hub strategies.
- EMA’s OPEN framework includes Japan’s PMDA/MHLW, Korea’s MFDS, and Australia’s TGA as non-EU partners that can evaluate selected medicines in parallel with EMA.
- BD teams should treat regulatory ecosystem depth as a scored site criterion alongside talent and clinical infrastructure—not as a soft narrative after the lease is signed.
What is driving the ecosystem-over-geography shift?
Cost-led site picks treated APAC mainly as a manufacturing floor. That model underweights regulatory trust, reliance pathways, and how fast a hub can support global filings.
WHO’s WLA framework answers Member State demand for a transparent, evidence-based designation that replaces older “stringent regulatory authority” labels used mainly for procurement.
Which APAC regulators signal ecosystem maturity?
On 31 October 2023, WHO listed Singapore’s Health Sciences Authority, Korea’s Ministry of Food and Drug Safety, and Switzerland’s Swissmedic as the first WHO-Listed Authorities.
A WLA is documented to meet WHO indicators for the requested scope after benchmarking and performance evaluation. That listing is a hard ecosystem signal for firms siting regional HQ, CMC, or clinical operations.
- First WLA cohort (Oct 2023): HSA (Singapore), MFDS (Korea), Swissmedic
- Purpose: enable reliance, procurement confidence, and resource-efficient review
- Implication: hubs with WLA status compete on regulatory trust, not only wages
How did the May 2024 WHO listings change the map?
WHO’s 20 May 2024 announcement approved the US FDA and the European medicines regulatory network (European Commission, EMA, and 30 national authorities) as WLAs.
Singapore’s HSA also received an expanded WLA scope covering market surveillance and control across medicines and biotherapeutics. That expansion matters for companies using Singapore as a dual Asia–West gateway.
Where does EMA OPEN fit APAC location strategy?
EMA’s OPEN framework lets non-EU regulators evaluate certain medicines in parallel with EMA while staying scientifically independent.
OPEN partners include Japan’s MHLW/PMDA, Korea’s MFDS, Australia’s TGA, plus Brazil’s ANVISA, Health Canada, Swissmedic, and WHO. Scope covers antimicrobials, PRIME products, high unmet need, and public-health threat medicines. EMA extended OPEN beyond the COVID pilot in July 2023.
Japan’s PMDA English portal is the operational face of that OPEN partnership for sponsors planning Asia–EU dual pathways.
How should pharma teams adapt site selection?
Replace single-metric cost ranking with an ecosystem audit refreshed at least annually:
- Regulator status: WLA listing and scope (medicines, biotherapeutics, surveillance)
- International linkage: EMA OPEN, ICH participation, reliance arrangements
- Operational depth: trial startup speed, GMP inspectorate capacity, IP enforcement
Second-tier hubs can still win specialized assets if they invest in translational infrastructure—even without Shanghai- or Singapore-scale density—provided the regulatory pathway is predictable.
What remains unproven?
WHO and EMA documents do not publish a ranked “best APAC city” list or guarantee that WLA/OPEN status alone cuts time-to-approval for every modality. Pipeline-share and patent-count claims from commercial consultancies are outside allowlisted primary sources here and are omitted.
Teams should verify each candidate site against primary regulator pages and their own asset class (small molecule, biologic, advanced therapy) before locking capital.
Related NovaPharma coverage
- Illumina APAC strategy under Nilesh Shah
- AI tools transforming clinical trials in life sciences
- Poly Medicure appoints Indranil Mukherjee as CEO, APAC & India
Frequently Asked Questions
What does ecosystem over geography mean for APAC site selection?
It means scoring regulatory maturity, reliance pathways, and innovation networks ahead of pure geographic cost arbitrage. WHO-Listed Authority status and EMA OPEN partnerships are concrete ecosystem signals BD teams can verify.
Which APAC regulators hold WHO-Listed Authority recognition?
Singapore’s Health Sciences Authority and Korea’s Ministry of Food and Drug Safety were among the first three WHO-Listed Authorities named on 31 October 2023. In May 2024 WHO expanded HSA’s WLA scope and added the US FDA and the European medicines network.
How should pharma teams audit an APAC life sciences hub?
Score WLA or OPEN participation, local agency capacity, clinical-trial startup pathways, and IP enforcement—then refresh that audit as WHO listings and EMA partner arrangements change.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
